# 2026-22842: DEA Raises Quotas for Amphetamines and Other Medicines Immediately

2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h), is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-11-10, effective 2026-11-10; PRIA reads it as touching household money (as of 2026-11-11).

- Canonical: https://policyrisk.com/federal-register/2026-22842
- As of: 2026-11-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-22842
- Title: Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 72564
- Published: 2026-11-10
- Effective: 2026-11-10
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-11

## In one line

DEA Raises Quotas for Amphetamines and Other Medicines Immediately

## Summary

The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.

## Abstract

The Drug Enforcement Administration (DEA) is adjusting the 2026 aggregate production quota for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). In making this determination, DEA has considered the factors set forth in 21 CFR 1303.13(b) in accordance with 21 U.S.C. 826(a) and is expediting publication of this determination to comply with the timeframes specified in 21 U.S.C. 826(h)(1).

## Effects PRIA read

- d,l‑Amphetamine Production Increase: benefit, high. If you take d,l-amphetamine medicines, the DEA raised the 2026 production limit from 24,234,443 grams to 31,654,915 grams, effective November 10, 2026. The agency says this increase is to address reported domestic shortages and let manufacturers ramp up production and maintain reserve stocks immedi…
- d‑Amphetamine (for Sale) Quota Raised: benefit, high. If you use d-amphetamine (for sale) products, the DEA raised the 2026 production limit from 26,450,000 grams to 37,108,041 grams, effective November 10, 2026. The increase responds to FDA-identified shortages and higher domestic and global medical need so manufacturers can increase output and build…
- Hydromorphone Quota Increased for Injectables: benefit, high. If you need hydromorphone injectable products, the DEA raised the 2026 production limit from 1,949,378 grams to 2,356,798 grams, effective November 10, 2026. The agency cites reported domestic shortages, a predicted 20.9 percent increase in domestic medical need for 2026, and a projected 142 percen…
- Methylphenidate (for Sale) Quota Raised: benefit, high. If you use methylphenidate products, the DEA raised the 2026 production limit from 58,283,000 grams to 69,502,651 grams, effective November 10, 2026. DEA based the increase on FDA reports of domestic shortages, a predicted 23.4 percent increase in domestic medical need for 2026, and predicted globa…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22717](https://policyrisk.com/federal-register/2026-22717): Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance, 2026-11-06
- [2026-22555](https://policyrisk.com/federal-register/2026-22555): Importer of Controlled Substances Application: Diamond Animal Health, Inc., 2026-11-05

## Sources
- [2026-22842 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/10/2026-22842/adjustment-to-the-2026-aggregate-production-quota-for-dl-amphetamine-d-amphetamine-for-sale)
- [2026-22842 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-10/pdf/2026-22842.pdf)

## Related
- [Previous: 2026-22840, Notice of Removal of Designated Chinese Military Company](https://policyrisk.com/federal-register/2026-22840)
- [Next: 2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substance…](https://policyrisk.com/federal-register/2026-22843)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-22842 (as of 2026-11-11).